Home › Compare › NPACY vs ABBV
NPACY yields 5.15% · ABBV yields 3.06%● Live data
📍 NPACY pulled ahead of the other in Year 1
Combined, NPACY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NPACY + ABBV for your $10,000?
Quadient S.A. provides business solutions for customers through digital and physical channels in France and internationally. The company offers customer experience management, business process automation, mail-related solutions, and parcel locker solutions. It provides Quadient Inspire, a software solution that helps businesses design, manage, and send personalized, omnichannel communications in large volumes. The company also offers Quadient Impress, a multichannel outbound document management platform; YayPay, account receivable process automation solutions; and Beanworks, accounts payable solution automating error-prone manual processes. In addition, it provides lines of software and hardware for preparing and sending mails in low and high volumes. Further, the company operates a pick-up, drop-off solution that offers businesses and people who need to manage their deliveries and returns. Additionally, it distributes print finishing equipment, such as guillotines, binding machines, laminating machines, and paper folding machines; provides professional and maintenance services; shipping software solutions; and automated packaging solutions. It serves financial services, healthcare, higher education, insurance, public sectors/government, retail, service providers, shipping carriers, telecommunications, and utilities industries. The company was formerly known as Neopost S.A. and changed its name to Quadient S.A. in September 2019. Quadient S.A. was founded in 1924 and is headquartered in Bagneux, France.
Full NPACY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.